Search results for "Highlights"

Results 221 - 230 of about 418 for "Highlights".
Sort by: Relevance | Newest | Oldest

Intensive BP control associated with worse CV outcomes in type 2 diabetes and recent ACS

A post hoc analysis found that patients with baseline systolic blood pressure (BP) <120 mm Hg or >160 mm Hg or follow-up BP <130 mm Hg had a significantly increased risk for a composite outcome of death from cardiovascular (CV) causes, nonfatal myocardial infarction, and nonfatal stroke.
9 Nov 2018

New consensus statement on type 2 diabetes changes recommended drugs

The recommendations from the American Diabetes Association and the European Association for the Study of Diabetes encourage use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
12 Oct 2018

Insulin pumps reduced ketoacidosis, hypoglycemia in young patients with type 1 diabetes

The results provide further evidence that insulin pump therapy is safe and effective, even in routine diabetes care for unselected patients, according to the study authors.
13 Oct 2017

Cardiovascular event rates similar between once-weekly exenatide and placebo in patients with type 2 diabetes

A limitation of the industry-funded randomized trial was the high rate of early discontinuation: 43.0% of patients on exenatide and 45.2% of those on placebo.
13 Oct 2017

Dapagliflozin appears effective as adjunct therapy in patients with type 1 diabetes

Patients with type 1 diabetes taking dapagliflozin for 24 weeks had lower HbA1c level, body weight, and insulin dose than those on placebo, according to the industry-funded study.
13 Oct 2017

Type 1 diabetes associated with increased atrial fibrillation risk, particularly in women

Risk of atrial fibrillation increased with worse glycemic control and renal complications. Among patients with normoalbuminuria, researchers found no excess risk of atrial fibrillation with an HbA1c less than 9.7% for men or 8.8% for women.
8 Sep 2017

Tool may help stratify risk for hypoglycemia-related ED and hospital use

The hypoglycemia risk stratification tool is based on six variables: previous episodes of hypoglycemia-related hospital utilization, insulin use, sulfonylurea use, ED use in the previous year, chronic kidney disease stage, and age.
8 Sep 2017

Second-line therapies for type 2 diabetes may offer similar glycemic control

The only significant difference found by the meta-analysis was a small increase in myocardial infarction and eye disorders with sulfonylureas compared with dipeptidyl peptidase-4 inhibitors.
14 Sep 2018

Switching to sulfonylureas from metformin monotherapy may increase risk of cardiovascular, hypoglycemic events

The results suggest that continuing metformin alone and accepting higher HbA1c targets may be preferable to switching to sulfonylureas when considering macrovascular outcomes and hypoglycemia, an accompanying editorial said.
10 Aug 2018

Metformin appears to prevent type 2 diabetes, study indicates

Results from the Diabetes Prevention Program Outcomes Study also showed that metformin was cost-effective compared to placebo for patients at high risk of diabetes.
11 Aug 2017

Result Page: Prev   18   19   20   21   22   23   24   25   26   27   Next